Cutaneous marginal zone B-cell lymphoma treated with rituximab

Marginal zone B-cell lymphoma (MZL) is probably the most frequent of the primary cutaneous B-cell lymphomas, which are entities with indolent behavior. Clinically, it appears in middle-aged patients as papules, nodules or erythematous plaques, solitary or multiple, on the trunk and proximal part of...

Full description

Saved in:
Bibliographic Details
Published in:Actas dermo-sifiliográficas 2005-11, Vol.96 (9), p.593-597
Main Authors: Pedraz, Javier, Delgado, Yolanda, Aragüés, Maximiliano, Fraga, Javier, García-Díez, Amaro, Fernández-Herrera, Jesús
Format: Article
Language:Spanish
Subjects:
Adult
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents - therapeutic use
Humans
Lymphoma, B-Cell - drug therapy
Male
Rituximab
Skin Neoplasms - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Marginal zone B-cell lymphoma (MZL) is probably the most frequent of the primary cutaneous B-cell lymphomas, which are entities with indolent behavior. Clinically, it appears in middle-aged patients as papules, nodules or erythematous plaques, solitary or multiple, on the trunk and proximal part of the limbs. The prognosis is excellent despite frequent cutaneous recurrences. We present the case of a 40-year-old male who, after having several recurrences of MZL over a ten-year period, was treated with rituximab for multiple skin lesions. The patient showed full remission after four weeks of treatment, and developed cytokine-release syndrome after the first infusion of the drug.
ISSN:0001-7310
DOI:10.1016/S0001-7310(05)73142-2